摘要
树突状细胞(Dendritic Cells,DC)作为抗原递呈细胞中的佼佼者,不仅具有强大的抗原递呈能力,还在免疫耐受中扮演着关键角色。如何利用DC的免疫耐受特性来治疗自身免疫性疾病,已成为免疫学研究的热点。重症肌无力作为一种T细胞依赖、抗体介导、器官特异的自身免疫病,其治疗也迎来了新的突破点——利用DC的免疫耐受特性。近年来,围绕DC的耐受特性、诱导耐受机制及其利用细胞因子诱导获得耐受性DC、DC负载乙酰胆碱受体或免疫优势肽段、基因修饰DC、特异性抑制核因子κB依赖的基因表达等治疗重症肌无力应用研究不断增多,为这一疾病的治疗提供了新的思路和方向。
Dendritic cells(DC),as outstanding antigen-presenting cells,not only possess powerful antigen-presenting capabilities but also play a crucial role in immune tolerance.How to harness the immune tolerance characteristics of DC to treat autoimmune diseases has become a hot topic in immunological research.Myasthenia gravis,as a T cell-dependent,antibody-mediated,organ-specific autoimmune disease,has seen a new breakthrough in treatment—utilizing the immune tolerance properties of DC.In recent years,research on the tolerance characteristics of DC,the mechanisms of inducing tolerance,and the application of cytokine-induced tolerogenic DC,DC loaded with acetylcholine receptors or immunodominant peptides,genetically modified DC,and specific inhibition of nuclear factor-κB-dependent gene expression for the treatment of myasthenia gravis has been increasing.These studies provide new insights and directions for the treatment of this disease.
作者
贺伊涵
文颖娟
张帅
王兴兵
张锦虹
陈亚莉
胥冰
HE Yihan;WEN Yingjuan;ZHANG Shuai;WANG Xingbing;ZHANG Jinhong;CHEN Yali;XU Bing(Shaanxi University of Chinese Medicine,Xianyang 712046,China;The First Clinical Medical College,Shaanxi University of Chinese Medicine,Xianyang 712046)
出处
《现代中医药》
2025年第2期9-15,共7页
Modern Chinese Medicine
基金
国家自然科学基金项目(81202642)
陕西省重点研发计划(S2023-YF-YBSF-0969)。
